Fig 1A summarizes the growth-promoting and survival pathways that can be targeted by NR4A1 antagonists in lung, pancreatic and colon cancer cells [14–17], and this study investigates these pathways in RCC cells and the role of C-DIM/NR4A1 antagonists as inhibitors of these pathways. Here, NR4A1 is linked to malignant colon neoplasm.